Clinical Trials Logo

Interstitial Pneumonia clinical trials

View clinical trials related to Interstitial Pneumonia.

Filter by:

NCT ID: NCT06068647 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Ultrasound and Respiratory Physiological Signals in Lung Diseases

SAURON
Start date: March 22, 2023
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT05758571 Recruiting - Neoplasms Malignant Clinical Trials

Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients

Start date: January 5, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Epigallocatechin-3-gallate (EGCG) is a major polyphenol of green tea that possesses a wide variety of actions, such as anti-inflammatory, anti-fibrotic, pro-apoptotic, anti-tumorous, and metabolic effects via modulation of a variety of intracellular signaling cascades. In addition, preclinical studies have also emphasized the antiviral activity of epigallocatechin-3-gallate (EGCG), including SARS-CoV-2. In previous studies, we found that EGCG can prevent and cure radiation-induced normal tissue damage in tumor patients. In clinical studies, we found that EGCG can prevent and treat radiation-induced acute radiation esophagitis, acute radiation skin injury, acute radiation oral mucositis with high safety. Thus, we designed this phase I-II clinical study in order to investigate the possible role of EGCG in the treatment interstitial pneumonia in tumor patients.

NCT ID: NCT05007457 Recruiting - Covid19 Clinical Trials

The Effectiveness of Respiratory Tele-rehabilitation After COVID-19 Pneumonia Related: a Randomized Controlled Trial

Start date: June 12, 2021
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT04507893 Completed - Covid19 Clinical Trials

Comparison Between Positive and Negative COVID-19 Pneumonia

Start date: March 15, 2020
Phase:
Study type: Observational
Read more »
NCT ID: NCT04441502 Active, not recruiting - Covid19 Clinical Trials

Identification of Predictors for the Evolution of COVID-19 Related Pneumonia by Transcriptomic and Seroproteomic

COVID_OMICS
Start date: March 30, 2020
Phase:
Study type: Observational

The investigating group aims at performing an observational, prospective study that involves the evaluation of circulating biomarkers predictive of clinical evolution in patients suffering from COVID-19 disease. In particular, the aim will be to verify whether there are transcripts or cytokines / chemokines in peripheral blood, modulated differently in patients with COVID-19, distinguished on the basis of the evolution towards more severe clinical pictures that require patient intubation or that show signs of cardiovascular damage. The study will be based on the transcriptional analysis of the entire genome and serum protein to evaluate the expression of a broad spectrum of cytokines and chemokines. Genome analysis will allow the genotype to be correlated to the identified gene expression profiles.

NCT ID: NCT04335019 Completed - Clinical trials for Interstitial Pneumonia

Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +

eChoVid
Start date: April 2, 2020
Phase:
Study type: Observational
Read more »
NCT ID: NCT03950583 Recruiting - Clinical trials for Interstitial Pneumonia

The Clinical Course of Interstitial Pneumonia With Autoimmune Features

Start date: June 12, 2019
Phase:
Study type: Observational

Interstitial pneumonia with autoimmune features (IPAF) is a chronic interstitial lung disease (ILD) with some laboratoristic and/or clinical features of autoimmune disease, but without meeting criteria of connective tissue disease (CTD), and with no other causes of ILD. Despite recent efforts to standardize the diagnosis of IPAF, subjects with IPAF represent a very heterogenous group of patients, whose prognosis and clinical course are far from being clear. It also remains to be clarified what proportion of IPAF patients develop clear features of CTD over time. The aim of this observational trial is to define the clinical course of patients newly diagnosed with IPAF by prospectively following them for a period of 3 years, at 6-month intervals. The primary outcome will be 3-year lung transplant-free survival. The secondary outcome will be the proportion of patients who develop clinical and laboratoristic features clearly meeting criteria for a diagnosis of CTD at 3 years from the time of diagnosis of IPAF. Predictors of survival will also be studied.

NCT ID: NCT03870828 Not yet recruiting - Clinical trials for Interstitial Lung Disease

Clinical Characteristics of Interstitial Pneumonia With Autoimmune Features (IPAF) - a Multicenter Prospective Study

Start date: March 18, 2019
Phase:
Study type: Observational

Interstitial pneumonia with autoimmune features (IPAF) was defined in 2015 by the Working Group of the European Respiratory Society (ERS) and the American Thoracic Society (ATS) as interstitial pneumonia with some clinical and/or serological features suggesting presence of an underlying autoimmune disorder. However, ofiicial criteria for diagnosis of an autoimmune disease are not met. Aims of the study: 1. Determine the incindence of IPAF in comparison with interstitial lung diseases (ILDs) and classic autoimmune diseases (ADs) in polish pulmonological centers. 2. Clinical, serological, functional and radiological and histopathological characteristics of IPAF patients. 3. Analysis of diagnostic strategies towards specific IPAF subgroups. 4. Characterictics of potencial diagnostic, predictive and prognostic features of IPAF. 5. Prospective assessment of IPAF patients in the courseof 5 years in order to determine stability of the diagnosis and potential progression to other diseases, e.g. ADs.

NCT ID: NCT02246023 Completed - Lung Cancer Clinical Trials

Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy

Start date: January 2015
Phase: Phase 4
Study type: Interventional

After randomization, the subjects undergo flexible bronchoscopy either with fractionated propofol administration or with propofol-TCI. Measurement of blood pressure, heart rate, oxygen saturation, and oxygen requirement are measured continuously during the procedure and thereafter. Cumulative propofol dose, and induction, procedure, and recovery time are noted continuously during and after the procedure.

NCT ID: NCT01154998 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Case-Control Study of Fibrotic Interstitial Lung Disease (ILD) and Cardiac Disease / Interventions.

Start date: July 2010
Phase: N/A
Study type: Observational

There is a rare condition causing scarring of the lungs termed interstitial lung disease. This comprises a group of conditions which can be divided into separate diseases. The aim of this study is compare a group of patients (the cases) with 2 types of this disease (fibrotic non-specific interstitial pneumonia (NSIP) and idiopathic pulmonary fibrosis (IPF)) with patients without the disease. The study will look at the 2 groups and their exposures to factors such as medications, smoking, previous jobs, previous medical problems and specifically heart disease and any operations or procedures involving the heart. There have been previous studies showing a link between heart disease and scarring of the lungs. This study will look at whether this association is stronger in one or the other type of lung scarring diseases.